There are a number of specific details that investors in Johnson & Johnson (NYSE:JNJ) should know about its stock. The slideshow below covers a handful of them, walking readers through a broad but brief analysis of the pharma giant from a shareholder's perspective.
The slideshow shows, among other things, that Johnson & Johnson rewards investors in multiple ways:
- It pays out more than half of its earnings via dividends, contributing to a 2.9% dividend yield compared to the S&P 500's 2.1%.
- It bought back $6.2 billion worth of its own stock over the past 12 months, translating into a 1.6% decrease in Johnson & Johnson's outstanding share count.
- And even though its shares yield more than the S&P 500, its share price has nevertheless kept up with the large cap index, outperforming it by six percentage points over the past decade.
To learn more about Johnson & Johnson, scroll through the slideshow below, which walks viewers through an analysis of the pharmaceutical heavyweight.
John Maxfield has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.